share_log

We Like The Quality Of LifeTech Scientific's (HKG:1302) Earnings

We Like The Quality Of LifeTech Scientific's (HKG:1302) Earnings

我們喜歡生命科技 (HKG: 1302) 收益的質素
Simply Wall St ·  2022/04/29 06:23

The market seemed underwhelmed by last week's earnings announcement from LifeTech Scientific Corporation (HKG:1302) despite the healthy numbers. We did some digging, and we think that investors are missing some encouraging factors in the underlying numbers.

上週的收益公告似乎令市場留下深刻的印象 先健科技公司 (港編號:1302)儘管數字健康。我們做了一些挖掘,我們認為投資者在基礎數字中缺少一些令人鼓舞的因素。

View our latest analysis for LifeTech Scientific

查看我們有關先健科技的最新分析

SEHK:1302 Earnings and Revenue History April 28th 2022
聯交所代碼:1302 二二二二年四月二十八日收益及收入歷

The Impact Of Unusual Items On Profit

不尋常的項目對利潤的影響

Importantly, our data indicates that LifeTech Scientific's profit was reduced by CN¥51m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect LifeTech Scientific to produce a higher profit next year, all else being equal.

重要的是,我們的數據顯示,先生科技的利潤比去年減少了人民幣 51 萬元,由於不尋常的項目。看到花費公司利潤的不尋常項目永遠不會很好,但從好處來看,事情可能會更早而不是晚些時候改善。我們研究了數以千計的上市公司,發現不尋常的物品往往是一次性的。鑑於這些行項目被認為是不尋常的,這並不令人驚訝。假設這些不尋常的開支不會再出現,因此,我們預計先生科技明年會產生更高的利潤,其他一切都是平等的。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of LifeTech Scientific.

注意: 我們始終建議投資者檢查資產負債表強度。點擊此處查看我們對先健科技的資產負債表分析。

Our Take On LifeTech Scientific's Profit Performance

我們對生命科技的利潤表現的看法

Unusual items (expenses) detracted from LifeTech Scientific's earnings over the last year, but we might see an improvement next year. Because of this, we think LifeTech Scientific's earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at an extremely impressive rate over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about LifeTech Scientific as a business, it's important to be aware of any risks it's facing. Every company has risks, and we've spotted 1 warning sign for LifeTech Scientific you should know about.

不尋常的項目(開支)從先健科技過去一年的收入減少,但明年我們可能會有所改善。因此,我們認為先健科技的盈利潛力至少與看起來一樣好,甚至更好!最重要的是,在過去三年中,其每股收益以極其令人印象深刻的速度增長。當然,我們只是在分析收益時才剛剛表現出來;除了其他因素外,人們還可以考慮利潤率,預測增長和投資回報率。如果您想了解更多有關先生科技企業的信息,請務必了解其面臨的任何風險。每家公司都有風險,我們已經發現了您應該了解的 1 個先生科技警告標誌。

Today we've zoomed in on a single data point to better understand the nature of LifeTech Scientific's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了一個數據點,以更好地了解先健科技的利潤性質。但是,還有很多其他方法可以通知您對公司的意見。有些人認為高股權回報是優質業務的好兆頭。所以大家不妨看看這個 自由 集合擁有高股權回報率的公司, 或這個名單的股票,內部人士正在購買.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?關注內容? 取得聯繫 直接與我們聯繫。 或者,通過電子郵件發送電子郵件給編輯團隊。
這篇文章由簡單牆聖是一般性質. 我們僅使用公正的方法,根據歷史數據和分析師預測提供評論,我們的文章並不打算作為財務建議。 它並不構成購買或出售任何股票的建議,也不會考慮您的目標或您的財務狀況。我們的目標是為您帶來由基本數據驅動的長期集中分析。請注意,我們的分析可能不會考慮最新的價格敏感公司公告或定性材料。簡易華街在提及的任何股票中都沒有倉位。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論